Insight Molecular Diagnostics Inc.

DB:7OC0 Stock Report

Market Cap: €180.7m

Insight Molecular Diagnostics Management

Management criteria checks 2/4

Insight Molecular Diagnostics' CEO is Josh Riggs, appointed in Dec 2022, has a tenure of 3.42 years. total yearly compensation is $2.59M, comprised of 18.2% salary and 81.8% bonuses, including company stock and options. directly owns 0.12% of the company’s shares, worth €214.75K. The average tenure of the management team and the board of directors is 3 years and 5.3 years respectively.

Key information

Josh Riggs

Chief executive officer

US$2.6m

Total compensation

CEO salary percentage18.20%
CEO tenure3.4yrs
CEO ownership0.1%
Management average tenure3yrs
Board average tenure5.3yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Josh Riggs's remuneration changed compared to Insight Molecular Diagnostics's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2026n/an/a

-US$48m

Dec 31 2025US$3mUS$472k

-US$50m

Sep 30 2025n/an/a

-US$61m

Jun 30 2025n/an/a

-US$63m

Mar 31 2025n/an/a

-US$58m

Dec 31 2024US$786kUS$385k

-US$61m

Sep 30 2024n/an/a

-US$44m

Jun 30 2024n/an/a

-US$37m

Mar 31 2024n/an/a

-US$40m

Dec 31 2023US$725kUS$340k

-US$26m

Sep 30 2023n/an/a

-US$22m

Jun 30 2023n/an/a

-US$17m

Mar 31 2023n/an/a

-US$11m

Dec 31 2022US$514kUS$242k

-US$19m

Compensation vs Market: Josh's total compensation ($USD2.59M) is above average for companies of similar size in the German market ($USD804.01K).

Compensation vs Earnings: Josh's compensation has increased whilst the company is unprofitable.

CEO

Josh Riggs (42 yo)

3.4yrs
Tenure
US$2,594,786
Compensation

Mr. Joshua Riggs, also known as Josh, serves as Director of Insight Molecular Diagnostics Inc. (formerly known as OncoCyte Corporation) since February 28, 2023, serves as its Chief Executive Officer & Pres...

Leadership Team

NamePositionTenureCompensationOwnership
Joshua Riggs
President3.4yrsUS$2.59m0.12%
€ 214.7k
Andrea James
Chief Financial Officer1.9yrsUS$1.68m0.64%
€ 1.2m
James Liu
VP of Accounting3.7yrsUS$454.99k0%
€ 0
Yuh-Min Chiang
Chief Technology Officer3yrsno datano data
Ekkehard Schutz
Chief Science Officer3.3yrsUS$633.57k0.064%
€ 115.6k
Peter Hong
VP, General Counsel & Secretary2.3yrsno datano data
Steven Tahmooressi
Vice President of Marketingno datano datano data
Sandra O'Donald
Senior Vice President of Business Operations2.8yrsno datano data
Paul Billings
Consulting Chief Medical Officer1.3yrsno datano data
Michael West
Scientific Advisor10.6yrsUS$328.84kno data
Gabrielle Woody
Sr. Executive Assistantno datano datano data
3.0yrs
Average Tenure
43yo
Average Age

Experienced Management: 7OC0's management team is considered experienced (3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Joshua Riggs
President3.3yrsUS$2.59m0.12%
€ 214.7k
Louis Silverman
Independent Director3.5yrsUS$191.83k0.0048%
€ 8.7k
Andrew Arno
Independent Chairman10.9yrsUS$312.63k0.30%
€ 543.9k
Daniel Hayes
Member of Scientific & Medical Advisory Board5.3yrsno datano data
David R. Gandara
Member of Scientific & Medical Advisory Boardno datano datano data
Robert Ferris
Member of Scientific & Medical Advisory Boardno datano datano data
John Kirkwood
Member of Scientific & Medical Advisory Board5.3yrsno datano data
Andrew Last
Independent Director10.4yrsUS$191.83k0.014%
€ 25.2k
Fred Hirsch
Member of Scientific & Medical Advisory Board5.3yrsno datano data
Heinz-Josef Lenz
Member of Scientific & Medical Advisory Board5.3yrsno datano data
Ignacio Wistuba
Member of Scientific & Medical Advisory Board5.3yrsno datano data
5.3yrs
Average Tenure
65.5yo
Average Age

Experienced Board: 7OC0's board of directors are considered experienced (5.3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/29 00:45
End of Day Share Price 2026/05/29 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Insight Molecular Diagnostics Inc. is covered by 8 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Paul KnightBrean Capital Historical (Janney Montgomery)
Mark MassaroBTIG
null nullKeyBanc Capital Markets Inc.